National Narcotics Leadership Act Amendments Act of 1993

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``National Narcotics Leadership Act 
Amendments of 1993''.

SEC. 2. IMPLEMENTATION OF NATIONAL DRUG CONTROL STRATEGY.

    Section 1003(c) of the National Narcotics Leadership Act of 1988 
(21 U.S.C. 1502(c)) is amended--
            (1) by redesignating paragraphs (5), (6), and (7) as 
        paragraphs (6), (7), and (8), respectively; and
            (2) by inserting after paragraph (4) the following:
    ``(5) The Director may require the inclusion, in the budget 
submission to the Office of Management and Budget by any National Drug 
Control Program agency, of funding requests for specific initiatives 
that are consistent with the President's priorities for the National 
Drug Control Strategy and certifications made pursuant to paragraph 
(3).''.

SEC. 3. REPORT ON REPROGRAMMING; OFFICE PERSONNEL RESTRICTION.

    (a) Report on Reprogramming.--Section 1003(c)(7) of the National 
Narcotics Leadership Act of 1988, as redesignated by section 2(1) of 
this Act, is amended to read as follows:
    ``(7) The Director shall report to the Congress on a quarterly 
basis regarding the need for any reprogramming or transfer of 
appropriated funds in an amount greater than $5,000,000 for National 
Drug Control Program activities.''.
    (b) Office Personnel Restriction.--Section 1003 of the National 
Narcotics Leadership Act of 1988 (21 U.S.C. 1502) is amended by adding 
at the end the following:
    ``(f) Prohibition on Political Campaigning.--A Federal officer in 
the Office of National Drug Control Policy who is appointed by the 
President, by and with the advice and consent of the Senate, may not 
participate in Federal election campaign activities, except that such 
an official is not prohibited by this subsection from making 
contributions to individual candidates.''.

SEC. 4. NATIONAL DRUG CONTROL STRATEGY OUTCOME MEASURES.

    Section 1005(a) of the National Narcotics Leadership Act of 1988 
(21 U.S.C. 1504(a)) is amended--
            (1) in paragraph (2)(A) by inserting ``and the consequences 
        of drug abuse'' after ``drug abuse''; and
            (2) by amending paragraph (4) to read as follows:
            ``(4) The Director shall include with each National Drug 
        Control Strategy an evaluation of the effectiveness of Federal 
        drug control during the preceding year. The evaluation shall 
        include an assessment of Federal drug control efforts, 
        including--
                    ``(A) assessment of the reduction of drug use, 
                including estimates of drug prevalence and frequency of 
                use as measured by national, State, and local surveys 
                of illicit drug use and by other special studies of--
                            ``(i) high-risk populations, including 
                        school dropouts, the homeless and transient, 
                        arrestees, parolees, and probationers, and 
                        juvenile delinquents; and
                            ``(ii) drug use in the workplace and the 
                        productivity lost by such use;
                    ``(B) assessment of the reduction of drug 
                availability, as measured by--
                            ``(i) the quantities of cocaine, heroin, 
                        and marijuana available for consumption in the 
                        United States;
                            ``(ii) the amount of cocaine and heroin 
                        entering the United States;
                            ``(iii) the number of hectares of poppy and 
                        coca cultivated and destroyed;
                            ``(iv) the number of metric tons of heroin 
                        and cocaine seized;
                            ``(v) the number of cocaine processing labs 
                        destroyed;
                            ``(vi) changes in the price and purity of 
                        heroin and cocaine;
                            ``(vii) the amount and type of controlled 
                        substances diverted from legitimate retail and 
                        wholesale sources; and
                            ``(viii) the effectiveness of Federal 
                        technology programs at improving drug detection 
                        capabilities at United States ports of entry;
                    ``(C) assessment of the reduction of the 
                consequences of drug use and availability, which shall 
                include estimation of--
                            ``(i) burdens drug users placed on hospital 
                        emergency rooms in the United States, such as 
                        the quantity of drug-related services provided;
                            ``(ii) the annual national health care 
                        costs of drug use, including costs associated 
                        with people becoming infected with the human 
                        immunodeficiency virus and other communicable 
                        diseases as a result of drug use;
                            ``(iii) the extent of drug-related crime 
                        and criminal activity; and
                            ``(iv) the contribution of drugs to the 
                        underground economy, as measured by the retail 
                        value of drugs sold in the United States; and
                    ``(D) determination of the status of drug treatment 
                in the United States, by assessing--
                            ``(i) public and private treatment capacity 
                        within each State, including information on the 
                        number of treatment slots available in relation 
                        to the number actually used, including data on 
                        intravenous drug users and pregnant women;
                            ``(ii) the extent, within each State, to 
                        which treatment is available, on demand, to 
                        intravenous drug users and pregnant women;
                            ``(iii) the number of drug users the 
                        Director estimates could benefit from 
                        treatment; and
                            ``(iv) the success of drug treatment 
                        programs, including an assessment of the 
                        effectiveness of the mechanisms in place 
                        federally, and within each State, to determine 
                        the relative quality of substance abuse 
                        treatment programs, the qualifications of 
                        treatment personnel, and the mechanism by which 
                        patients are admitted to the most appropriate 
                        and cost effective treatment setting.
            ``(5) The Director shall include with the National Drug 
        Control Strategy required to be submitted not later than 
        February 1, 1994, and with every second such strategy submitted 
        thereafter--
                    ``(A) an assessment of the quality of current drug 
                use measurement instruments and techniques to measure 
                supply reduction and demand reduction activities;
                    ``(B) an assessment of the adequacy of the coverage 
                of existing national drug use measurement instruments 
                and techniques to measure the casual drug user 
                population and groups at-risk for drug use;
                    ``(C) an assessment of the actions the Director 
                shall take to correct any deficiencies and limitations 
                identified pursuant to subparagraphs (A) and (B); and
                    ``(D) identification of the specific factors that 
                restrict the availability of treatment services to 
                those seeking it and proposed administrative or 
                legislative remedies to make treatment available to 
                those individuals.
            ``(6) Federal agencies responsible for the collection or 
        estimation of drug-related information required by the Director 
        shall cooperate with the Director, to the fullest extent 
        possible, to enable the Director to satisfy the requirements of 
        sections 4 and 5.
            ``(7) By June 1, 1994, and with each National Drug Control 
        Strategy submitted thereafter, the Director shall report to the 
        President and the Congress on the Director's assessment of drug 
        use and availability in the United States, including an 
        estimate of the effectiveness of interdiction, treatment, 
        prevention, law enforcement, and international programs under 
        the National Drug Control Strategy in effect in the preceding 
        year in reducing drug use and availability.''.

SEC. 5. DIRECTOR AS A MEMBER OF THE NATIONAL SECURITY COUNCIL.

    Section 402(a)(7) of title 50, United States Code, is amended by--
            (1) striking ``and'' after the semicolon in paragraph (6);
            (2) redesignating paragraph (7) as paragraph (8); and
            (3) inserting after paragraph (6) the following:
            ``(7) the Director of the Office of National Drug Control 
        Policy; and''.

SEC. 6. COUNTER-DRUG TECHNOLOGY ASSESSMENT CENTER.

    (a) Drug Abuse Addiction and Rehabilitation Center.--Section 1003A 
of the National Narcotics Leadership Act of 1988 (21 U.S.C. 
1502a(c)(1)) is amended--
            (1) by redesignating subparagraphs (B), (C), and (D) as 
        subparagraphs (C), (D), and (E), respectively; and
            (2) by inserting after subparagraph (A) the following:
                    ``(B) identify and support, through interagency 
                agreements or grants that are subjected to peer review 
                by independent advisory boards, the application of 
                technology to expanding the effectiveness or 
                availability of drug treatment;''.
    (b) Assistance From the Advanced Research Project Agency.--Section 
1003A of the National Narcotics Leadership Act of 1988 (21 U.S.C. 
1502a) is amended by adding at the end the following:
    ``(f) Assistance and Support to Office of National Drug Control 
Policy.--The Director of the Advanced Research Project Agency shall, to 
the fullest extent possible, render assistance and support to the 
Office of National Drug Control Policy and its Director.''.
    (c) Repeal and Redesignation.--The National Narcotics Leadership 
Act of 1988 is amended by--
            (1) repealing section 1008 (21 U.S.C. 1505), as in effect 
        on the date of the enactment of this Act;
            (2) redesignating section 1003A, as amended by subsection 
        (b) of this section, as section 1008; and
            (3) moving such section, as redesignated, so as to follow 
        section 1007.

SEC. 7. PAYING CERTAIN NECESSARY EXPENSES FOR STRATEGY CONSULTATION.

    Section 1005(a)(3) of the National Narcotics Leadership Act of 1988 
(21 U.S.C. 1504(a)(3)) is amended by adding at the end the following:
    ``(C) The Director may pay for the necessary and appropriate 
expenses for assemblages of individuals providing consultation to the 
Director in developing the National Drug Control Strategy.''.

SEC. 8. AUTHORIZATION OF APPROPRIATIONS.

    Section 1011 of the National Narcotics Leadership Act of 1988 (21 
U.S.C. 1508) is amended by striking ``$3,500,000'' and all that follows 
through ``years,'' and inserting ``such sums as may be necessary for 
fiscal year 1994,''.

SEC. 9. TERMINATION OF OFFICE OF NATIONAL DRUG CONTROL POLICY.

    Section 1009 of the National Narcotics Leadership Act of 1988 (21 
U.S.C. 1506) is amended by striking ``the date which is 5 years after 
the date of the enactment of this subtitle'' and inserting ``September 
30, 1994''.

            Passed the House of Representatives November 21, 1993.

            Attest:

                                           DONNALD K. ANDERSON,

                                                                 Clerk.

Summary: National Narcotics Leadership Act Amendments of 1993 - Amends the National Narcotics Leadership Act of 1988 to authorize the Director for National Drug Control Policy to require the budget submission to the Office of Management and Budget by any National Drug Control Program agency to include funding requests for specific initiatives that are consistent with the President's priorities for the National Drug Control Strategy and certifications made regarding the adequacy of such request to implement the objectives of the Strategy for the relevant year. 
(Sec. 3) Requires the Director to report to the Congress on a quarterly basis regarding the need for any reprogramming or transfer of appropriated funds for Program activities in an amount greater than $5 million.  Prohibits a Federal officer in the Office of National Drug Control Policy who is appointed by the President from participating in Federal election campaign activities, except that such an official is not thereby prohibited from making contributions to individual candidates. 
(Sec. 4) Revises provisions regarding the Strategy to:  (1) include long-range goals for reducing the consequences of drug abuse; and (2) require the Director to include an evaluation of the effectiveness of Federal drug control during the preceding year. 
Specifies that such evaluation shall include an assessment of Federal drug control efforts, including:  (1) an assessment of the reduction of drug use, drug availability, and associated consequences (such as the burdens drug users place on hospital emergency rooms); and (2) a determination of the status of U.S. drug treatment. 
Requires:  (1) the Director to include with the Strategy specified information regarding assessment of drug use measurement, identification of factors restricting the availability of treatment, and proposed remedies to make such treatment available and to report to the President and the Congress on drug use and availability in the United States; and (2) Federal agencies responsible for the collection or estimation of drug-related information to cooperate with the Director to satisfy such requirements. 
(Sec. 5) Designates the Director as a member of the National Security Council. 
(Sec. 6) Requires:  (1) the Director to identify and support, through interagency agreements or grants that are subjected to peer review by independent advisory boards, the application of technology to expanding the effectiveness or availability of drug treatment; and (2) the Director of the Advanced Research Project Agency to assist and support the Office and its Director.  Repeals provisions of the Act pertaining to an executive reorganization study. 
(Sec. 7) Authorizes the Director to pay the expenses for assemblage of individuals providing consultation in developing the Strategy. 
(Sec. 8) Authorizes appropriations. 
(Sec. 9) Terminates the Office on September 30, 1994.